Herpes zoster: Difference between revisions

No edit summary
(22 intermediate revisions by 8 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Caused by [[varicella zoster virus]] (VZV) causing [[Varicella]] (chicken pox) and later zoster (shingles)  
*Also known as shingles
*Virus is dormant in dorsal root ganglion and reactivates causing characteristic rash in dermatomal distribution  
*Caused by [[varicella zoster virus]] (VZV; also known as Human Herpes Virus 3) causing [[Varicella]] (chicken pox) and later zoster (shingles)  
*Virus is dormant in dorsal root ganglion and reactivates causing characteristic vesiculopapular rash in dermatomal distribution  
*Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV)
*Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV)


===Prevention===
===Prevention===
*Pt is contagious until lesions are crusted over  
*Patient is contagious until lesions are crusted over  
*Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts
*Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts
*Zoster vaccination if >60
*Zoster vaccination if >60
Line 14: Line 15:
==Clinical Features==
==Clinical Features==
*Prodrome: Headache, malaise, photophobia  
*Prodrome: Headache, malaise, photophobia  
*Antecedent pruritis, paresthesia, pain to dermatome 2-3 days prior to rash  
*Antecedent pruritus, paresthesia, pain to dermatome 2-3 days prior to rash  
*Maculopapular rash (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days  
*Maculopapular rash (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days  
*Does not cross midline  
*Does not cross midline  
*Typically affects chest/face
*Typically affects chest/face
*Lumbar and sacral dermatomes may display skin sparing between the feet and groin
*V3 involvement can present initially as dental pain


==Differential Diagnosis==
==Differential Diagnosis==
*[[Smallpox]]
{{Bullous rashes DDX}}
*[[Cellulitis]]
*Contact Dermatitis
*[[Measles]]
 
{{VZV types}}
{{VZV types}}


==Diagnostic Evaluation==
==Evaluation==
===Workup===
===Workup===
*Generally a clinical diagnosis
*Generally a clinical diagnosis
Line 46: Line 45:


==Management==
==Management==
*Analgesia
===Analgesia===
*Antiviral
*Analgesia is very important and should be prescribed along with an antiviral
**Reduces risk/duration of postherpetic neuralgia
*Consider Lidocaine patch, NSAIDS, oral opioids, or gabapentin
**Immunocompetent patients:  
*Diphenhydramine and ranitidine for itch/pain
***Give [[acyclovir]] if <72hr of onset of rash or >72hr if new vesicles present/developing<ref>Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674</ref>  
 
***[[Acyclovir]] 800mg PO 5x/day x 7d
===Antiviral===
**Immunosuppressed patients:  
*Reduces risk/duration of postherpetic neuralgia with dosing based on immune status and time course of disease
***Give antiviral therapy at any stage of onset of rash  
*Not effective in treating postherpetic neuralgia once it has developed
***[[Acyclovir]] 10 mg/kg IV q8h OR 800mg PO 5x/day x 7d or foscarnet for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, recent transplant
'''Immunocompetent patients:'''
*[[Acyclovir]] 800mg PO 5x/day x 7d if <72hr of onset of rash or >72hr if new vesicles present/developing<ref>Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674</ref>  
*[[Valacyclovir]] (can also be given but is generally more expensive than acyclovir)
**1g PO q8hrs (CrCl normal)
**1g PO q12hrs (CrCl 30-49 mL/min)
**1g PO q24hrs (CrCl 10-29 mL/min(
**500mg q24hrs PO (CrCl < 10ml/min)
'''Immunosuppressed patients:'''
*Antiviral therapy should be given regardless of the time of onset of rash  
*[[Acyclovir]] 10mg/kg IV q8h OR 800mg PO 5x/day x 7d or [[Foscarnet]] for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, or recent transplant
*Isolation precautions
**Disseminated zoster requires airborne precautions


===Not Beneficial===
===Glucocorticoids===
*Steroids not shown to be beneficial
*Steroids not shown to be beneficial<ref>He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008.</ref>


==Disposition==
==Disposition==
Line 68: Line 78:
*[[Impetigo]]
*[[Impetigo]]
*[[Necrotizing Fasciitis]]
*[[Necrotizing Fasciitis]]
*[[SIADH]]


==See Also==
==See Also==

Revision as of 22:41, 3 November 2018

Background

  • Also known as shingles
  • Caused by varicella zoster virus (VZV; also known as Human Herpes Virus 3) causing Varicella (chicken pox) and later zoster (shingles)
  • Virus is dormant in dorsal root ganglion and reactivates causing characteristic vesiculopapular rash in dermatomal distribution
  • Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV)

Prevention

  • Patient is contagious until lesions are crusted over
  • Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts
  • Zoster vaccination if >60
Herpes Zoster
Herpes Zoster

Clinical Features

  • Prodrome: Headache, malaise, photophobia
  • Antecedent pruritus, paresthesia, pain to dermatome 2-3 days prior to rash
  • Maculopapular rash (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days
  • Does not cross midline
  • Typically affects chest/face
  • Lumbar and sacral dermatomes may display skin sparing between the feet and groin
  • V3 involvement can present initially as dental pain

Differential Diagnosis

Vesiculobullous rashes

Febrile

Afebrile

Varicella zoster virus

Evaluation

Workup

  • Generally a clinical diagnosis
  • May consider viral Culture, antigen, PCR of vesicle fluid

Evaluation

  • Confirm that the patient does not have:
  • Consider further evaluation for immunocompromized state (may be initial presentation of HIV) if:
    • Disseminated
    • If more than 3 or more dermatomes affected
    • Atypical illness/severe disease
  • In immunocompromized patients consider further evaluation for:

Management

Analgesia

  • Analgesia is very important and should be prescribed along with an antiviral
  • Consider Lidocaine patch, NSAIDS, oral opioids, or gabapentin
  • Diphenhydramine and ranitidine for itch/pain

Antiviral

  • Reduces risk/duration of postherpetic neuralgia with dosing based on immune status and time course of disease
  • Not effective in treating postherpetic neuralgia once it has developed

Immunocompetent patients:

  • Acyclovir 800mg PO 5x/day x 7d if <72hr of onset of rash or >72hr if new vesicles present/developing[1]
  • Valacyclovir (can also be given but is generally more expensive than acyclovir)
    • 1g PO q8hrs (CrCl normal)
    • 1g PO q12hrs (CrCl 30-49 mL/min)
    • 1g PO q24hrs (CrCl 10-29 mL/min(
    • 500mg q24hrs PO (CrCl < 10ml/min)

Immunosuppressed patients:

  • Antiviral therapy should be given regardless of the time of onset of rash
  • Acyclovir 10mg/kg IV q8h OR 800mg PO 5x/day x 7d or Foscarnet for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, or recent transplant
  • Isolation precautions
    • Disseminated zoster requires airborne precautions

Glucocorticoids

  • Steroids not shown to be beneficial[2]

Disposition

  • Admit for disseminated VZ, CNS involvement, severely immunosupressed
  • Healing of lesions may take 4 or more weeks[3]

Complications

See Also

References

  1. Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674
  2. He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008.
  3. Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84(3):274–280.